Zepbound

• 12/28/2024

  Tirzepatide Access in Jeopardy: Patients Face Uncertain Future

• 12/26/2024

  Obesity Drug Setback Sparks Retail Rush into Novo Nordisk

• 12/23/2024

  FDA Greenlights Revolutionary Sleep Apnea Treatment, Offering New Hope to Millions

• 12/23/2024

  Tirzepatide Shortage Ends: What It Means for Patients and Pharmacies

• 12/8/2024

  Market Pulse: Winners, Losers, and Surprises

• 12/8/2024

  Zepbound vs Wegovy: New Obesity Treatment Wins in Head-to-Head Trial

• 11/23/2024

  Eli Lilly and Pfizer: What’s Next for Big Pharma’s Powerhouses?

• 11/13/2024

  Weight-Loss Giants Face Uncertainty: Can They Adapt to Changing Market?

• 11/10/2024

  Eli Lilly Stock: High Expectations Meet Reality Check

• 11/1/2024

  Eli Lilly’s Weight Loss and Diabetes Drugs Miss Sales Expectations Amid Inventory Issues